Eli Lilly Wegovy Rival: New Obesity Pill Announced
Summary of the Article: Oral Obesity Pills – Orforglipron (Eli Lilly) vs. oral Semaglutide (Novo Nordisk)
This article discusses the potential impact of two new oral obesity medications - orforglipron from Eli Lilly and oral semaglutide from Novo Nordisk – and analyzes their strengths and weaknesses. Here’s a breakdown of the key points:
1.Efficacy Concerns (Orforglipron):
Analysts believe the recent trial data for Eli Lilly’s orforglipron won’t considerably change doctors’ prescribing habits. The weight loss results were seen as incremental and not dramatically different from existing options.
2. Side Effects:
Both drugs share similar gastrointestinal side effects (nausea, vomiting).
Orforglipron had a discontinuation rate of 10.3% at the highest dose due to side effects, compared to 2.6% on placebo. 24% reported vomiting, 33.7% nausea. Novo Nordisk’s oral semaglutide had higher rates of vomiting (30.9%) and nausea (46.6%).
Experts are still evaluating the persistence of these side effects with more complete data. It’s currently unclear which drug has a better tolerability profile.
3. Practicality & Dietary Requirements:
Novo Nordisk’s oral semaglutide has strict dietary requirements: must be taken on an empty stomach with only 4oz of water, and patients must wait 30 minutes before eating or taking other medications. This is seen as a potential barrier to adherence.
Eli Lilly’s orforglipron doesn’t have these restrictions, making it potentially more convenient.
4. Manufacturing & Pricing:
Oral semaglutide (Novo Nordisk) is expected to be more expensive to manufacture due to being a peptide medication. This likely means a higher price point than orforglipron.
Orforglipron, being a small molecule, is generally cheaper to produce. Eli lilly hasn’t announced pricing yet, but analysts predict it will be comparable to their injectable drugs (Zepbound/Mounjaro – over $1,000/month).
* Novo Nordisk is investing heavily in US manufacturing ($24 billion over the past decade) to support production.
In essence, the article suggests a competitive landscape where convenience (orforglipron) and established manufacturing (Novo Nordisk) will be key factors alongside efficacy and price. The final pricing decisions will be crucial in determining which drug gains wider market acceptance.